- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00890175
Staccato Loxapine Pulmonary Safety in Patients With Asthma
March 13, 2017 updated by: Alexza Pharmaceuticals, Inc.
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma
The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Allergy and Asthma Medical Group & Research Center, A.P.C.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- History of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator FEV1 ≥60% of predicted value.
Exclusion Criteria:
- History of COPD, or any other acute or chronic pulmonary disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Inhaled loxapine @ 0 & 10 h
Inhalation of 10 mg of loxapine at 0 and 10 hours
|
10 mg, 2 doses, 10 hours apart
Other Names:
|
PLACEBO_COMPARATOR: Inhaled placebo @ 2 & 10 hours
Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
|
placebo, 2 doses, 10 hours apart
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in FEV1 from baseline by spirometry
Time Frame: at each post-treatment time point (15 min to 34 hr)
|
at each post-treatment time point (15 min to 34 hr)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in FVC from baseline by spirometry
Time Frame: at each post-treatment time point (15 min to 34 hr)
|
at each post-treatment time point (15 min to 34 hr)
|
Treatment emergent adverse events
Time Frame: Post-treatment time points
|
Post-treatment time points
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
August 1, 2009
Study Registration Dates
First Submitted
April 27, 2009
First Submitted That Met QC Criteria
April 28, 2009
First Posted (ESTIMATE)
April 29, 2009
Study Record Updates
Last Update Posted (ACTUAL)
March 15, 2017
Last Update Submitted That Met QC Criteria
March 13, 2017
Last Verified
August 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- Loxapine
Other Study ID Numbers
- AMDC-004-105
- 10 April 2009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD submitted to regulatory authorities.
Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Inhaled loxapine @ 0 & 10 h
-
Alexza Pharmaceuticals, Inc.Completed
-
Alexza Pharmaceuticals, Inc.Atlanta Center for Medical ResearchCompleted
-
Alexza Pharmaceuticals, Inc.Completed
-
Alexza Pharmaceuticals, Inc.CompletedPatients With Schizophrenia and Acute AgitationUnited States
-
Alexza Pharmaceuticals, Inc.Completed
-
University Hospital, Basel, SwitzerlandRecruitingNSTEMI - Non-ST Segment Elevation MI | Acute Chest PainUnited Kingdom, Switzerland, Spain, Korea, Republic of, United States, Australia, Austria, Finland, Greece, Italy, Romania
-
Alexza Pharmaceuticals, Inc.Completed
-
Ohio State UniversityRecruitingNutritional RequirementsUnited States
-
Alexza Pharmaceuticals, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States